Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Kazia agrees to sell Cantrixil IP and trademark rights to Vivesto

Kazia Therapeutics (NASDAQ:KZIA) announced it will receive $1 million for the sale of all intellectual property (IP) and trademark rights of Cantrixil to Vivesto (Nasdaq Stockholm:VIVE). Vivesto licensed the exclusive...

March 31, 2025

Developments

Neural shares commence trading on Frankfurt Stock Exchange

Neural Therapeutics (CSE:NURL) announced that shares of the company have commenced trading on the Frankfurt Stock Exchange under symbol “M6B”. The company is developing therapeutics to address mental illnesses related...

March 31, 2025

Developments

Leap reports positive Phase 2 data of sirexatamab in MSS CRC

Leap Therapeutics (NASDAQ:LPTX) announced positive updated data from its Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy, compared to bevacizumab...

March 26, 2025

Developments

Coya reports progress of first-in-class Treg-derived exosome program

Coya Therapeutics (NASDAQ:COYA) announced a status update of its investigational regulatory T cell-derived exosome—Treg exosomes—platform for the treatment of systemic and neurodegenerative diseases driven by chronic...

March 26, 2025

Developments

Sunshine enters agreement to market generic antibiotics in Canada

Sunshine Biopharma (NASDAQ:SBFM) announced that it has signed an agreement to market two new generic antibiotics in Canada through its wholly owned Canadian subsidiary, Nora Pharma, subject to regulatory approval...

March 25, 2025

Developments

Oncotelic completes Phase 1 study of OT-101 and IL-2 in metastatic solid tumors

Oncotelic Therapeutics (OTCQB:OTLC) announced it has completed Phase 1 of its trial evaluating OT-101 in combination with IL-2 for advanced metastatic tumors. According to Oncotelic, this announcement coincides with a...

March 25, 2025

Developments

Can-Fite launches FDA/EMA-approved Phase 3 trial of Piclidenoson in psoriasis

Can-Fite BioPharma (NYSE American:CANF) announced that it has initiated a pivotal Phase 3 study of its oral drug Piclidenoson for the treatment of psoriasis, with FDA- and EMA-approved protocol. According to Can-Fite...

March 24, 2025

Developments

First patients recruited into Ondine’s Steriwave ICU pilot study

Ondine Biomedical (LON:OBI) announced the initiation of patient recruitment for an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New Westminster, British Columbia. The company states that...

March 20, 2025

Developments

USPO issues NOA to Sonnet for second IL-18 protein patent

Sonnet BioTherapeutics (NASDAQ:SONN) announced that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) for a second patent in the IL-18 variant protein field. According to...

March 19, 2025

Developments

Bioxytran signs NDA with UGA to evaluate galectin antagonist for bird flu

Bioxytran (QTCQB:BIXT) announced that it has signed a non-disclosure agreement (NDA) with the board of regents of the University System of Georgia, University of Georgia (UGA), to collaborate on evaluating its galectin...

March 19, 2025

Developments

Final patient enrolled in Biofrontera’s Phase 3 trial of Ameluz in AKs

Biofrontera (NASDAQ:BFRI) announced completion of patient enrollment in the Phase 3 study of Ameluz topical gel for the treatment of Actinic Keratoses (AKs) on the extremities, neck, and trunk with photodynamic therapy...

March 18, 2025

Developments

Capricor reveals positive data from HOPE-2 trial of deramiocel in DMD

Capricor Therapeutics (NASDAQ:CAPR) announced positive long-term data from its on-going HOPE-2 trial demonstrating the potential of its lead candidate, deramiocel, to slow disease progression and preserve upper limb...

March 17, 2025

Developments

Perimeter reaches regulatory milestone with FDA PMA submission for next-gen B-Series OCT with ImgAssist AI 2.0

Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) announced that it has filed a premarket approval (PMA) application for its next-generation B-Series OCT system, which combines proprietary AI technology with optical...

March 17, 2025

Developments

Biovica partners with Outcomes4Me to support HR-positive mBC patients

Biovica International (STO:BIOVIC-B; FRA:911) announced that it has partnered with Outcomes4Me to support post-menopausal patients with hormone (HR)-positive metastatic breast cancer (mBC) in understanding treatment...

March 12, 2025

Developments

Atossa announces plan to pursue MBC indication for (Z)-endoxifen

Atossa Therapeutics (NASDAQ:ATOS) announced its decision to pursue a metastatic breast cancer (MBC) indication for (Z)-endoxifen. According to Attosa, it also plans to work with the FDA to advance additional...

March 11, 2025

Developments

Trevi reports positive Phase 2a trial data of Haduvio for RCC

Trevi Therapeutics (NASDAQ:TRVI) announced positive topline results from its Phase 2a RIVER study of oral nalbuphine ER (Haduvio) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)...

March 10, 2025

Developments

PDS launches Phase 3 trial for HNSCC

PDS Biotechnology (NASDAQ:PDSB) announced that it has commenced its Phase 3 trial, VERSATILE-003, to evaluate the efficacy and safety of Versamune HPV plus pembrolizumab for head and neck squamous cell carcinoma (HNSCC)...

March 10, 2025

Developments

Covenant Health Fort Sanders first in Tennessee to use Perimeter’s pioneering AI-driven OCT cancer margin visualization technology

Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX:PYNKF) announced that Covenant Health Fort Sanders Regional is the first hospital in Tennessee to implement its optical coherence technology (OCT) technology, S-Series...

March 6, 2025

Developments

Oragenics submits IB for Phase 2 trial of ONP-002 in mTBI

Oragenics (NYSE American:OGEN) announced the submission of an Investigator Brochure (IB) in preparation for its Phase 2 trial evaluating ONP-002 for mild traumatic brain injury (mTBI), commonly known as concussion...

March 6, 2025

Developments

SIR accepts Autonomix abstract showcasing study results

Autonomix Medical (NASDAQ:AMIX) announced that the Society of Interventional Radiology (SIR) has accepted its abstract highlighting its technology and early proof-of-concept study results for a poster presentation at...

March 6, 2025

Developments

EPO to grant Moleculin’s Annamycin new patent allowances strengthening global exclusivity

Moleculin Biotech (NASDAQ:MBRX) announced that it received a Notice of Intent to Grant from the European Patent Office (EPO) for its patent application covering Annamycin, a potential next-generation, non-cardiotoxic...

March 6, 2025

Developments

Arch announces non-brokered private placement

Arch BioPartners (TXSV:ARCH; QTCQB:ACHFF) has arranged a non-brokered private placement of 225,806 common shares at $1.55 per share, generating proceeds of CAD $350,000. According to Arch, the offering, set to close...

March 5, 2025

Subscribe